Orantinib
Orantinib (NSC 702827) is a potent, selective inhibitor of PDGFR (Ki = 8 nM), Flk-1, and FGFR1 tyrosine kinases, with minimal activity against IGF-1R, Met, Src-family kinases, Abl, CDK2, and EGFR. It has been utilized in preclinical cancer research, demonstrating anti-angiogenic and antitumor efficacy in various in vitro and in vivo models.
Product Specifications
CAS Number
252916-29-3
Product Name Alternative
Inhibit, NSC 702827, Orantinib, Platelet-derived growth factor receptor, NSC702827, NSC-702827, Fibroblast growth factor receptor, FGFR, FGFR1, Flk1, Inhibitor, Apoptosis, PDGFR, PDGFRβ, SU6668, SU-6668, SU 6668, Vascular endothelial growth factor receptor, VEGFR, TSU 68, TSU68, TSU-68
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
98.01% (May vary between batches)
Solubility
DMSO:40 mg/mL (128.89 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:10 mg/mL (32.22 mM) ;1eq. NaOH:31 mg/mL (99.89 mM)
Smiles
Cc1[nH]c (\C=C2/C (=O) Nc3ccccc23) c (C) c1CCC (O) =O
Molecular Formula
C18H18N2O3
Molecular Weight
310.35
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
